BioMaxima S.A. systematically introduces new products to the offer and improves already offered products. Since 2018, the BioMaxima Research and Development Centre (CBR) has been operating within the Special Economic Zone in Lublin, where development work is carried out for four of the company’s existing technological platforms: diffusion systems for drug sensitivity testing, microbiological substrates, rapid cassette tests and clinical chemistry.
CBR is currently working on rapid immunochromatographic assays for the detection of new parameters, as well as improving production technologies for already manufactured assays. In 2022, work was carried out on the E. coli O157 tests and modifications to the tests for the identification of Rotavirus/Adenovirus, Influenza A/B and C. difficile GDH/tox were developed. A/tox. B.
Within the framework of the project "Substrate for Cell Cultures" works towards the development of preparations and technologies used in cell cultures are carried out. This rapidly developing field, both in the medical, pharmaceutical and cosmetic sectors, presents many opportunities and challenges. Currently, we are working on the implementation for the production of: substrates, buffers and reagents for cell cultures. Further products are being designed, complementing the assortment.
Molecular techniques are one of the fastest developing areas in IVD, enabling relatively fast and very precise diagnostics. CBR is currently developing products for sampling, inactivation, isolation of genetic material, amplification, analysis of results as well as for long-term storage of genetic material. The aim of our work is to create solutions that will facilitate research and diagnostics in many microbiological, environmental, industrial and medical areas. In 2022, 8 items were introduced into production: isolation kits, PCR reagents, enzymes and buffers.
In the group of biochemical reagents, studies are carried out to develop complementary parameters to the wide range of products currently offered. The works also concern the modification of the current products, primarily with regard to the improvement of the durability of reagents and their most important functional parameters, as well as the optimization of production costs.
MARIA CURIE-SKŁODOWSKA UNIVERSITY IN LUBLIN. Faculty of Biology and Biotechnology
Between 2017 and 2022, the UMCS in Lublin, in cooperation with the Research and Development team of BioMaxima SA, conducted research towards the development of a technologically innovative method of obtaining gradient tests for the determination of susceptibility to antibiotics (MIC). The research was conducted by a team from the Department of Genetics and Microbiology and the Department of Biochemistry of UMCS. The project managers were Prof. Adam Choma and Prof. Anna Turska. As a result of the work, two patent applications were filed in 2022.
MEDICAL UNIVERSITY OF LUBLIN. Department and Department of Pharmaceutical Microbiology
Cooperation with BioMaxima SA included microbiological control of MIC test prototypes. The research coordinator was Prof. Anna Malm. In addition, on 4 May 2023, BioMaxima concluded a framework cooperation agreement with the Medical University of Lublin, including joint research and development activities.
UNIVERSITY OF WARSAW
On 17 April 2023, a conditional agreement was signed for research and development work on the development of primers for the Salmonella Real Time PCR LAB-KIT, Salmonella LAMP LAB-KIT and Listeria Multiplex Real Time PCR LAB-KIT, Listeria Multiplex LAMP LAB-KIT molecular test kits developed by the Research and Development Department of BioMaxima S.A.